Antibiotic could be the key to treating heart ailments

Nov 03, 2010 By Quinn Phillips
Dr. Rick Schulz and researcher Mohammad Ali have discovered that the MMD2 molecule is responsible for cutting an essential protein in heart tissue.

A researcher at the University of Alberta has discovered that treating basic heart ailments could be as simple as using a well-known antibiotic.

Richard Schulz, a professor of and in the Faculty of Medicine & Dentistry, and his team were looking at a specific type of cardiac injury called ischemia and reperfusion injury. This happens when a patient suffers a heart attack caused by a blockage in a coronary artery. The sooner the blockage is relieved by reperfusion, which is the resuming of the blood flow, the less overall damage the heart muscle receives and the better the recovery for the patient.

But in many types of heart disease the body’s largest protein, titin, is cut into pieces inside the heart. This is dangerous because titin is a major contributor in the heart’s filling and pumping action. What Schulz and his team discovered is that it’s a molecule found in the heart muscle—Matrix Metalloproteinase-2, or MMP2—that is cutting titin.

By targeting MMP2, Schulz says the occurrence of titin being cut will be significantly lessened. That targeting, or inhibiting of MMP2, can be done by using the tetracycline family of drugs, known for their effectiveness as and also used for acne sufferers,

“The exciting thing about this is that people have not considered using MMP inhibitors to treat very basic heart diseases,” said Schulz, who added it is an inexpensive drug that should be tested as a treatment for one of Canada’s top killers, cardiovascular disease.

Schulz is also thinking more broadly than just ischemia reperfusion, because ischemia reperfusion is a type of oxidative-stress injury to the heart, whereby the body produces too many chemically reactive molecules containing oxygen and this overwhelms the body’s anti-oxidant protective systems. Excess oxidative stress is thought to be the cause of a number of heart problems. Antioxidants might reduce the risk of this dangerous process, says Schulz, but as MMP2 is activated by oxidative stress, its inhibitors could be much more specific and effective drugs to use to treat patients with heart diseases.

“You find a kernel of where things could affect a lot of pathways to heart disease, whether it’s ischemia reperfusion or heart failure or transplant rejection,” said Schulz, whose work is funded by the Canadian Institutes of Health Research. “We have a feeling that this is something that could be used for a wide variety of diseases.”

Explore further: A real-time tracking system developed to monitor dangerous bacteria inside the body

More information: Schulz’s team will now test MMP2 inhibitors in a number of heart disease models. The results of this study were published in the Nov. 1 edition of Circulation.

add to favorites email to friend print save as pdf

Related Stories

Novel compound may lessen heart attack damage

Feb 07, 2008

A novel drug designed to lessen muscle damage from a heart attack has passed initial safety tests at the Duke Clinical Research Institute. Results of the study, available online and to be published in the February 19 issue ...

The benefits of reperfusion therapy

Sep 01, 2009

The wider use of reperfusion therapy in patients with heart attack (AMI) can save millions of lives in Europe. Effective reperfusion therapy in an AMI patient can cut the individual risk of dying by half. AMI is caused by ...

Recommended for you

Cause of ageing remains elusive

9 hours ago

A report by Chinese researchers in the journal Nature a few months ago was a small sensation: they appeared to have found the cause for why organisms age. An international team of scientists, headed by the ...

Newly discovered bacterial defence mechanism in the lungs

10 hours ago

A new study from Karolinska Institutet presents a previously unknown immunological mechanism that protects us against bacterial infections in the lungs. The study is being published in the American Journal of Respiratory an ...

User comments : 0